VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Lupeng Pharmaceutical Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Rocbrutinib (LP-168) vs. Pirtobrutinib
Lupeng Pharmaceutical Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Rocbrutinib (LP-168) vs. Pirtobrutinib
May 21, 2026 22:00 CST Updated May 22, 01:13
Share:
